Innovent Biologics (HKG:1801) agreed to license 12 early-stage cancer therapy programs to Pfizer for an upfront payment of $650 million, according to a Friday filing with the Hong Kong bourse.
The 12 oncology programs comprise eight Innovent-originated early-stage assets and four Pfizer-proposed discovery programs.
Under the agreement, Innovent will advance development of the assets through phase 1 clinical study, after which Pfizer will lead global development.
In addition to the upfront payment, Innovent is eligible to receive up to $9.85 billion in milestone payments, plus royalties on products that are commercialized.